Alterity Therapeutics Ltd Stock Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 85.78M 75.35M 69.42M 64.91M 122M 8.09B 124M 833M 323M 3.99B 322M 315M 13.87B | P/E 2026 * |
-0.23x | P/E 2027 * | -0.23x |
|---|---|---|---|---|---|
| Enterprise Value | 40.59M 35.66M 32.85M 30.72M 57.61M 3.83B 58.67M 394M 153M 1.89B 152M 149M 6.56B | EV / Sales 2026 * |
11.9x | EV / Sales 2027 * | 28.1x |
| Free-Float |
91.47% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 85.78M | |
| +1.67% | +9.28% | -5.05% | +1.40% | 46.36B | |
| +4.95% | +9.31% | +363.86% | +598.16% | 37.88B | |
| +0.44% | +11.12% | +17.47% | -12.91% | 31.12B | |
| -0.64% | +1.92% | +3.08% | +53.58% | 30.61B | |
| +0.23% | -0.29% | +13.24% | +21.10% | 24.69B | |
| +9.90% | +13.32% | - | - | 16.25B | |
| +1.40% | +12.99% | +67.11% | +132.76% | 14.85B | |
| +1.88% | +8.59% | +13.76% | +20.68% | 13.58B | |
| +2.38% | +5.69% | +95.85% | +97.63% | 12.95B | |
| Average | +2.42% | +8.21% | +71.16% | +114.05% | 25.36B | |
| Weighted average by Cap. | +2.20% | +8.01% | +79.88% | +132.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.42M 3.01M 2.77M 2.59M 4.86M 323M 4.95M 33.25M 12.88M 159M 12.86M 12.58M 554M | 1.6M 1.41M 1.3M 1.21M 2.27M 151M 2.31M 15.54M 6.02M 74.44M 6.01M 5.88M 259M |
| Net income | -13.44M -11.81M -10.88M -10.17M -19.08M -1.27B -19.43M -131M -50.56M -625M -50.48M -49.37M -2.17B | -22.29M -19.58M -18.04M -16.87M -31.63M -2.1B -32.22M -216M -83.83M -1.04B -83.7M -81.87M -3.6B |
| Net Debt | -45.19M -39.69M -36.57M -34.2M -64.13M -4.26B -65.31M -439M -170M -2.1B -170M -166M -7.3B | -40.88M -35.91M -33.09M -30.94M -58.02M -3.86B -59.09M -397M -154M -1.9B -154M -150M -6.61B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
